GlassScriptPhysician profile
Brian J Paugh
NPI 1225430416
$6,892.96
in general payments reported to CMS, 2019-2025
28 companies · $840 in 2025
The $840 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,956 · 2022: $1,530 · 2023: $1,769 · 2024: $798 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,328 · Education: $79.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,327.61 |
| Education | $79.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $788.96 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $768.76 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $738.88 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $721.45 | 2021-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $690.44 | 2021-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $497.00 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $469.04 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $363.25 | 2021-2023 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $278.36 | 2021-2025 | Rexulti, Nuedexta |
| Alkermes, INC. | $226.17 | 2021-2023 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $221.37 | 2021-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $194.32 | 2021-2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $167.45 | 2023-2025 | Quviviq, Quviviq |
| Sunovion Pharmaceuticals INC. | $129.05 | 2021-2022 | |
| Indivior INC. | $81.20 | 2022-2023 | Perseris |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $80.78 | 2023-2024 | Azstarys |
| Tris Pharma INC | $67.21 | 2021-2023 | Dyanavel Xr |
| Eisai INC. | $59.88 | 2021-2022 | |
| Almatica Pharma LLC | $57.93 | 2021-2022 | |
| Neos Therapeutics, LP | $56.17 | 2024-2025 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $53.31 | 2022-2023 | Belsomra |
| Collegium Pharmaceutical, INC. | $43.42 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $43.28 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.56 | 2024-2025 | Cobenfy |
| Neuronetics, INC. | $27.06 | 2021-2025 | Neurostar Tms Therapy System |
| Bausch Health US, LLC | $14.67 | 2022 | |
| Axsome Therapeutics, INC. | $13.66 | 2025 | Auvelity |
| Adlon Therapeutics L.P. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Paugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.